Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Metastatic Breast Cancer, End of Life
Phase Not Applicable
Enrollment 15
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

I this qualitative study, Investigators will conduct semi-structured interviews with clinicians that are involved in the care of patients with breast cancer to evaluate the acceptability, appropriateness, and feasibility/usability of a metastatic breast cancer-specific prognostic tool. These interviews will be conducted by the UNC CHAI Core and will continue until thematic saturation (estimated 10 participants). The investigators will code the qualitative data using emerging themes, guided by a well-established implementation science theory, the Consolidated Framework for Implementation Research (CFIR). The information gained from these studies will inform an implementation approach to increase the usability and acceptability of a novel prognostic tool to assist oncologists in the prognosis of patients with metastatic breast cancer.

Design

Study type: Observational Observational model: Ecologic Or Community Time perspective: Prospective

Interventions / Regimen

  • Behavioral: Clinician Qualitative Interview — Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications \& Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.

Primary Outcomes

  • Key barriers for use a metastatic breast cancer-specific prognostic tool (12 months)
  • Key facilitators for use of a metastatic breast cancer-specific prognostic tool (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-07-07
Completion: 2027-08-10
Eligibility
Age: Not reported
Sex: ALL
Volunteers: true
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNC Lineberger Comprehensive Cancer Center
Collaborators: Conquer Cancer Foundation
Principal Investigators:
  • Emily Ray, MD (PRINCIPAL_INVESTIGATOR) - University of North Carolina, Chapel Hill
Contact Information
Study Contact:
Terri Eubanks, BSBA
919-966-4530
teubanks@med.unc.edu
Erin Kelly, MPH, RD, LDN
919-966-0040
erin_kelly@med.unc.edu
Emily Ray, MD
emily_ray@med.unc.edu
University of North Carolina
Interventions
  • Behavioral: Clinician Qualitative Interview — Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications \& Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
Study Locations (1 sites)
University of North Carolina, Chapel Hill, North Carolina 27599 United States
Eligibility Criteria
Inclusion Criteria: 1. Verbal informed consent obtained to participate in the study. 2. Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee. 3. Physician, nurse practitioner, physician assistant, or nurse navigator 4. At least 6 months of experience in the clinical care of patients with metastatic breast cancer in the United States. Exclusion Criteria: * Non-English Speaking
Conditions Breast Cancer, TNBC - Triple-Negative Br...
Phase Not Applicable
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

18F-Fluoroestradiol (18F-FES) is an estrogen receptor-targeting positron emission tomography tracer with high sensitivity and specificity for the detection of estrogen receptor(ER)-positive tumors . 18F-FES has been used as a predictive biomarker to demonstrate estrogen receptor heterogeneity , to evaluate the pharmacokinetics of estrogen receptor-targeted drugs , to measure residual estrogen receptors during endocrine therapy and to determine biologically optimal doses of novel estrogen receptor-targeted drugs .This study aimes to explore the efficacy of 18F-FES PET/CT in evaluating the expression levels of ER in primary and metastatic breast cancer patients.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • SUVmax (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-12-31
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tongji Hospital
Principal Investigators:
  • ZHU XIAOHUA, DR (PRINCIPAL_INVESTIGATOR) - Tongji Hospital
Contact Information
Study Contact:
ZHU XIAOHUA, DR
13971513770
evazhu@vip.sina.com
xiaohua zhu, Dr.
TongjiHospital
Interventions
N/A
Study Locations (1 sites)
TongjiHospital, Wuhan, Hubei 430030 China
Eligibility Criteria
Inclusion Criteria: * More than 18 years old * Patients with pathologically confirmed breast cancer * Sign the informed consent form Exclusion Criteria: * Pregnant women * Severe underlying diseases that cannot cooperate with PET examination
Conditions Cancer Risk, Cancer Predisposition Syndr...
Phase Not Applicable
Enrollment 5000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal. * The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Samples — Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: Blood, Buccal swab (saliva) or mouthwash, Urine, Stool, Biopsy or surgical tissue (i.e., bone marrow),Bodily fluids, Other tissues

Primary Outcomes

  • Identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal. (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-04-25
Completion: 2031-03-25
Eligibility
Age: Not reported
Sex: ALL
Volunteers: true
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dana-Farber Cancer Institute
Principal Investigators:
  • Sapna Syngal, MD (PRINCIPAL_INVESTIGATOR) - Dana-Farber Cancer Institute
Contact Information
Study Contact:
Jenna Beckwith, MPH
857-215-1892
inadvancestudy@dfci.harvard.edu
Tia Kauffman, MPH
Sapna Syngal, MD
617-632-5022
SSYNGAL@PARTNERS.ORG
Dana Farber Cancer Institute
Interventions
  • Other: Samples — Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types: Blood, Buccal swab (saliva) or mouthwash, Urine, Stool, Biopsy or surgical tissue (i.e., bone marrow),Bodily fluids, Other tissues
Study Locations (1 sites)
Dana Farber Cancer Institute, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria: * Participants to be included in this study include the following (note that this list is not comprehensive but gives examples of precursor conditions for each organ type): 1-Hereditary risk for cancer including * Carriers of known or previously unrecognized pathogenic germline variants of cancer predisposing genes * Individuals with personal or family history suggestive of elevated cancer risk (this may include individuals who have negative genetic testing results or have not elected to undergo testing) * Individuals with a clinically based diagnosis of a Cancer Predisposition Syndrome (examples, neurofibromatosis, Fanconi Anemia, Ataxia-Telangiectasia) * Hereditary Cancer Prediction Model-based elevated cancer risk * Others at risk for specific cancers by virtue of exposure, obesity, gender, race and ethnicity, HPV exposure (for H\&N cancer for example), etc. * Exposed High Risk including * Childhood cancer survivors with treatment exposures associated with increased risk of cancer * Adult cancer survivors with treatment exposures associated with increased risk of cancer * Documented high level exposure to group 1 IARC carcinogens * Thoracic: individuals at risk for lung cancer including but not exclusive of the following criteria: Age \>50, Smoking history of \>15 pack years, First-degree relative history of lung cancer or COPD * alcoholic liver disease (NAFL), non-alcoholic steatohepatitis (NASH), cirrhosis * Precursor Lesions including * Breast: ductal/lobular carcinoma in situ (CIS) and atypical hyperplasia * GI: Barrett's esophagus, Pancreatic precursor lesions, colonic dysplasia/adenomata, nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), cirrhosis * GU: High grade prostatic epithelial neoplasia, and high-grade bladder urothelial dysplasia/carcinoma in situ, * Lung: Adenomatous hyperplasia * H\&N: high-risk oral precancerous diseases * Skin: Class II melanocytic lesions. Squamous dysplasia * Heme malignancies: CHIP, CCUS, ICUS, MGUS, SMM, SWM, MBL (spell these out), Low grade lymphomas * Thoracic: Lung nodules detected on screening CT that prompt further follow-up * GYN: STIC lesion (serous tubal intraepithelial carcinoma), Endometrial intraepithelial neoplasia, Cervical and endocervical carcinoma in situ, vulvar intraepithelial neoplasia * Pediatric histologic diagnoses sometimes associated with development of malignancy: Nephrogenic rests, benign bone lesions with risk of malignant degeneration (Giant cell tumor, osteochondroma), Spitz nevus, and others. * FAMILY MEMBERS or healthy individuals Exclusion Criteria: There are no exclusion criteria for the study. Note: Patients with prior cancer history are allowed to participate. Patients with prior history of cancer or non-metastatic localized cancers (such as skin cancer or localized prostate cancer) are allowed to be enrolled. Patients enrolled in clinical trials or receiving therapy for precursor diseases are NOT excluded from this study.

Phase I Human Analytics (HALO) Study

NCT05423860
Recruiting
Conditions Cardiovascular Diseases, Cancer, Dementi...
Phase Not Applicable
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Discover, optimize, standardize, and validate clinical-trial measures and biomarkers used to diagnose and differentiate cardiovascular, oncologic, neurologic, and other diseases and disorders. Specifically, our research study endeavors to improve disease and disorder diagnosis to the earliest clinical states, in preclinical states, and to develop ensemble multivariate biomarker risk scores leading to cardiovascular, oncologic, neurologic, and other diseases and disorders. Additionally, the study aims to: * Evaluate data analysis techniques to improve diagnostic accuracy and reduce time to diagnosis. * Evaluate data analysis techniques to improve risk stratification for participants through machine learning algorithms. * Direct participants to relevant and applicable clinical trials.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Other: no interventions will be performed (observational) — Not applicable. (no interventions will be performed with this observational study

Primary Outcomes

  • Prostate cancer Gleason score (Up to 5 years after treatment)
  • Prostate cancer ISUP grade group (Up to 5 years after treatment)
  • Prostate cancer staging parameters (Up to 5 years after treatment)
  • Prostate cancer specific mortality (Up to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-03-16
Completion: 2037-03
Eligibility
Age: 45 Years and older
Sex: MALE
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: HALO Diagnostics
Collaborators: HALO Affiliate Sites
Principal Investigators:
  • Christopher R. Hancock, MD (PRINCIPAL_INVESTIGATOR) - HALO Diagnostics
  • Erik W. Peterson, BS (STUDY_DIRECTOR) - HALO Diagnostics
Contact Information
Study Contact:
Christopher R Hancock, MD,MBA
760-776-8989
chris.hancock@halodx.com
Erik W Peterson
414-745-5773
ERIK.PETERSON@HALODX.COM
Bernadette M. Greenwood, MSc
760-766-2047
Desert Medical Imaging
Interventions
  • Other: no interventions will be performed (observational) — Not applicable. (no interventions will be performed with this observational study
Study Locations (1 sites)
Desert Medical Imaging, Indian Wells, California 92210 United States
Eligibility Criteria
Inclusion Criteria: Treatment Naïve patients: * Male, 45 years of age or older. * Diagnosis of prostate adenocarcinoma. * Clinical stage T1c or T2a. * Gleason score of 7 (3+4 or 4+3) or less. * Three or fewer biopsy cores with prostate cancer. * PSA density not exceeding 0.375. * One, two, or three tumor suspicious regions identified on multiparametric MRI. * Negative radiographic indication of extra-capsular extent. * Karnofsky performance status of at least 70. * Estimated survival of 5 years or greater, as determined by treating physician. * Tolerance for anesthesia/sedation. * Ability to give informed consent. * At least 6 weeks since any previous prostate biopsy. * MR-guided biopsy confirmation of one or more MRI-visible prostate lesion(s) with Gleason score of 7 (3+4 or 4+3) or less. Salvage candidates will be accepted upon physician referral. Exclusion Criteria: * Presence of any condition (e.g., metal implant, shrapnel) not compatible with MRI. * Severe lower urinary tract symptoms as measured by an International Prostate Symptom Score (IPSS) of 20 or greater * History of other primary non-skin malignancy within previous three years. * Diabetes * Smoker
Conditions Epithelial Ovarian Cancer, Triple Negati...
Phase PHASE1
Enrollment 70
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Study LCB-1801-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), first-in-human clinical study of NI-1801 in patients with advanced, metastatic, or recurrent solid malignancies expressing mesothelin (MSLN). The dose escalation part (Part A) of the main study will evaluate the safety and tolerability of escalating doses of NI-1801 to determine the maximum tolerated dose (MTD) and non-tolerated toxic dose (NTD) of NI-1801. The expansion part (Part B) of the main study will further evaluate the safety and efficacy of NI-1801 administered at or below the MTD in up to 10 additional subjects in order to determine the recommended Phase 2 dose (RP2D). Treatments will be administered in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. The dose escalation part (Part A) of the sub-study will evaluate the safety and tolerability of escalating doses of NI-1801 in combination with anti-PD-1 antibody. The expansion part (Part B) of the sub-study will further evaluate the safety and efficacy of NI-1801 administered in combination with anti-PD-1 antibody at or below the MTD. In the randomized cohort, the experimental arm will receive the investigational drug NI-1801 at the P2RD every two weeks in combination with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles. The control arm will be treated with weekly paclitaxel at the same regimen representing one of the standards of care (SoC) in this population. This trial specifically targets patients with platinum-resistant ovarian cancer. This cohort will be made up of 20 evaluable patients, 10 per arm.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Biological NI-1801 — Treatment will be administered in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Each subject will receive the assigned dose of NI-1801 on Cycle 1, Day 1. Subsequent doses will be given Q2W, which may be adjusted to every three weeks if recommended from the ongoing PK/PD model analysis.
  • Drug: NI-1801 in combination with anti-PD1 (Pembrolizumab) — In the combination with pembrolizumab cohort, the starting NI-1801 dose will be 300 mg. Pembrolizumab will be administered at the dosage of 400 mg every 6 weeks, in 4 cycles. Pembrolizumab will be administered as first drug; later, NI-1801 will be infused after 30 minutes.
  • Drug: NI-1801 in combination with paclitaxel — The experimental arm will receive the investigational drug NI-1801 at the P2RD every two weeks in combination with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles. The control arm will be treated with weekly paclitaxel at the same regimen.
  • Drug: Paclitaxel — The control arm will be treated with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles.

Primary Outcomes

  • Dose Limiting Toxicity (DLT) (Up to 12 months)
  • Non-Tolerated Dose (NTD) (Up to 12 months)
  • Maximum Tolerated Dose (MTD) (Up to 12 months)
  • Progression Free Survival (PFS) (Randomized Cohort only) (Up to 12 months)
  • Adverse Events (AEs) (Up to 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2022-04-29
Completion: 2026-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Light Chain Bioscience - Novimmune SA
Principal Investigators:
  • Chief Medical Officer, MD (STUDY_DIRECTOR) - LCB - Novimmune SA
Contact Information
Study Contact:
Clinical Project Manager
+41 79 26 83 513
ni1801clinical@lightchainbio.com
E. Romano, MD
Institut Curie
J. Medioni, MD
Hôpital Européen Georges Pompidou
Interventions
  • Drug: Biological NI-1801 — Treatment will be administered in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Each subject will receive the assigned dose of NI-1801 on Cycle 1, Day 1. Subsequent doses will be given Q2W, which may be adjusted to every three weeks if recommended from the ongoing PK/PD model analysis.
  • Drug: NI-1801 in combination with anti-PD1 (Pembrolizumab) — In the combination with pembrolizumab cohort, the starting NI-1801 dose will be 300 mg. Pembrolizumab will be administered at the dosage of 400 mg every 6 weeks, in 4 cycles. Pembrolizumab will be administered as first drug; later, NI-1801 will be infused after 30 minutes.
  • Drug: NI-1801 in combination with paclitaxel — The experimental arm will receive the investigational drug NI-1801 at the P2RD every two weeks in combination with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles. The control arm will be treated with weekly paclitaxel at the same regimen.
  • Drug: Paclitaxel — The control arm will be treated with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles.
Study Locations (7 sites)
Institut Curie, Paris, 75005 France
Hôpital Européen Georges Pompidou, Paris, 75015 France
Centre Eugène Marquis, Rennes, 35042 France
Gustave Roussy, Villejuif, France, 94800 France
Humanitas Research Hospital, Milan, 20089 Italy
Istituto Europeo di Oncologia, Milan, 20141 Italy
Centro Ricerche Cliniche Verona, Verona, 37134 Italy
Eligibility Criteria
Main Inclusion Criteria for the Single Agent Dose Escalation and the Combination with Pembrolizumab: 1. Adults ≥ 18 years of age at the time of signing the informed consent form 2. Histologically or cytologically confirmed diagnosis of epithelial OC (high-grade serous or endometroid), TNBC, or non-squamous NSCLC. For the combination with pembrolizumab, only subjects with histologically or cytologically confirmed diagnosis of epithelial OC (high-grade serous or endometroid), non-squamous NSCLC and ductal pancreatic adenocarcinoma. 3. MSLN expression with staining intensity of ≥ 2+ as per IHC in ≥ 40% of tumor cells. Staining for MSLN expression can be performed using archival tumor tissue and is foreseen to be performed at the institution's pathology. A slice for centralized IHC assessment for validation and biomarker analysis is mandatory. 4. Patients with advanced, metastatic, or recurrent disease * after at least 1 prior systemic treatment for the primary malignancy and * who have failed treatment with, are intolerant to, or are not candidates for available therapies that are known to confer a clinical benefit to patients with these tumor entities. 5. Measurable disease according to the revised RECIST guideline version 1.1(3) 6. Patients treated in either the single agent recommended dose expansion cohort or in the combination with pembrolizumab cohort should have accessible lesions at screening for baseline and on treatment biopsies. 7. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1. 8. Negative pregnancy test at inclusion. 9. Life expectancy of at least 2 months. Main Inclusion Criteria for the Randomized study arm: 1. Female patients ≥ 18 years of age. 2. Patients must have a confirmed diagnosis of high-grade serous epithelial ovarian cancer. 3. Patients must have platinum-resistant disease: 3.1. Patients who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response (CR or PR) and then progressed between greater than 3 months and ≤ 6 months after the date of the last dose of platinum. 3.2. Patients who have received 2 or 3 lines of platinum therapy must have progressed on or within 6 months after the date of the last dose of platinum 4. Patients must have progressed radiographically on or after their most recent line of therapy. 5. Patients must be willing to provide an archival tumor tissue block or slides, or undergo procedure to obtain a new biopsy using a low risk, medically routine procedure for IHC confirmation of MSLN expression. 6. MSLN expression with staining intensity of ≥ 2+ as per IHC in ≥ 40% of tumor cells. Staining for MSLN expression can be performed using archival tumor tissue and can be done at the institution's pathology. A slice for centralized IHC assessment for validation and biomarker analysis is mandatory. 7. Patients must have at least one lesion that meets the definition of measurable disease by RECIST v1.1 (radiologically measured by the Investigator). 8. Patients must have received at least 1 but no more than 3 prior systemic lines of anticancer therapy, and for whom single-agent therapy is appropriate as the next line of treatment: * Adjuvant ± neoadjuvant considered one line of therapy * Maintenance therapy (e.g., bevacizumab, PARP inhibitors) will be considered as part of the preceding line of therapy (i.e., not counted independently) * Therapy changed due to toxicity in the absence of progression will be considered as part of the same line (i.e., not counted independently) * Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance 9. ECOG PS of 0 or 1 10. Time from prior therapy: * Systemic antineoplastic therapy (5 half-lives or 4 weeks, whichever is shorter) * Focal radiation completed at least 2 weeks prior to first dose of study drug 11. Patients must have stabilized or recovered (Grade 1 or baseline) from all prior therapy-related toxicities. 12. Major surgery must be completed at least 4 weeks prior to first dose and have recovered or stabilized from the side effects of prior surgery. 13. Patients must have adequate hematologic, liver and kidney functions 14. Patients or their legally authorized representative must be willing and able to sign the informed consent form (ICF) and to adhere to the protocol requirements. 15. Negative pregnancy test at inclusion Main Exclusion Criteria for the Single Agent Dose Escalation and the Combination with Pembrolizumab: 1. Patient has known hypersensitivity to NI-1801 or any of the constituent compounds. 2. Radiotherapy to the target lesions within 4 weeks prior to the first NI-1801 infusion. 3. Prior anti-cancer therapy including chemotherapy, hormonal therapy, and investigational agents within 2 weeks or within ≤ 5 half-lives prior to starting NI-1801 dosing (up to a maximum of 4 weeks), whichever is longer. The maximum required washout period will thus not exceed 4 weeks prior to the day of first treatment with NI-1801. Note: Low dose steroids (oral prednisone or equivalent ≤ 20 mg per day, including systemic or topic use), localized noncentral nervous system (CNS) radiotherapy of non-target lesions, and treatment with bisphosphonates and RANKL inhibitors are not criteria for exclusion. 4. Other investigational therapies must not be used, i.e., treatment within another clinical trial is not permitted, while the patient is on study. COVID-19 vaccination is allowed only starting from Cycle 2 (if not completed before study inclusion). 5. Severe cardiac dysfunction (NYHA classification III-IV). 6. Significant hepatic dysfunction (serum bilirubin ≥ 1.5 mg/dL or AST and/or ALT ≥ 2.5 times normal level), unless related to liver metastasis. 7. Patients with known human immunodeficiency virus (HIV) infection or known history or serological evidence of prior hepatitis B or C virus infection. Active SARS-COV2 infection. 8. Uncontrolled active systemic bacterial, viral, fungal, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti-infective treatment within 2 weeks prior to first dose of NI-1801. 9. Patients with concomitant active malignancy, requiring ongoing systemic treatment. 10. Patients with known CNS metastases. 11. Platelet count lower than 100 x 10\^9/L (transfusion support within 14 days before the test is not allowed). 12. Hemoglobin lower than 10.0 g/dL. Prior RBC transfusion is permitted. 13. ANC lower than 1 x 10\^9/L (the use of colony stimulating factors, G-CSF or GM-CSF, within 14 days before the test is not allowed). 14. Pregnancy and lactation. 15. History of psychiatric illness or substance abuse likely to interfere with ability to comply with protocol requirements or give informed consent. 16. Significant medical diseases or conditions, including laboratory abnormalities, as assessed by the Investigators and Sponsor, which would substantially increase the risk-benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction within the last 6 months, unstable angina, uncontrolled diabetes mellitus, and severely immunocompromised state, major surgery ≤ 4 weeks prior to starting NI-1801. 17. Prior treatment with a CD47, SIRPα, or MSLN targeting agent. 18. Patients in whom acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure have not resolved to Grade ≤ 1 or returned to baseline except for alopecia (any grade), anemia, and peripheral neuropathy (for the latter, recovery to Grade ≤ 2 is acceptable). 19. People who are detained through a court or administrative decision, receiving psychiatric care against their will, adults who are the subject of a legal protection order (under tutorship/curatorship), people who are unable to express their consent, and people who are subject to a legal guard
Conditions Breast Cancer Classified as TNM Stage 0-...
Phase NA
Enrollment 790
Locations 17 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Research Purpose The present study is designed to generate the strongest evidence available on the role of robotic surgical systems in breast cancer surgery and to elucidate the clinical value of immediate breast reconstruction (IBR) conducted in conjunction with robot-assisted nipple-sparing mastectomy (RNSM). Study Design Overview This study is a prospective, multicenter, randomized clinical trial (ROM Trial) designed to compare the oncologic outcomes of robot-assisted nipple-sparing mastectomy (RNSM) with conventional nipple-sparing mastectomy (CNSM), which includes both traditional and open-chest approaches. Previous retrospective studies of robot-assisted endoscopic surgery have suggested a short learning curve, demonstrating technical feasibility and reproducibility even for less experienced surgeons. However, the absence of rigorously designed randomized clinical trials remains a major global barrier to the broader adoption of robotic breast surgery. In the ROM Trial, eligible patients who provide written informed consent will be randomly assigned in a 1:1 ratio to undergo either RNSM or CNSM. Participants will be blinded to group allocation until the day of surgery (single-blind design). Immediate breast reconstruction (IBR) will be performed in all patients, with the reconstruction method determined in consultation with the breast and/or plastic surgeon following mastectomy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Procedure: Robot-assisted Nipple-Sparing Mastectomy (RNSM) — Patients undergoing robot-assisted nipple-sparing mastectomy (RNSM) with immediate breast reconstruction (IBR) will be enrolled in this group. RNSM will be performed using robotic surgical platforms, including the da Vinci S, Si, X, Xi, and SP systems. The procedure will be conducted through an axillary or lateral chest wall incision. During surgery, posterior areolar tissue sampling for frozen section biopsy will be recommended. If suspicious lesions are detected at the superficial or posterior margins, frozen section biopsy of those lesions will also be performed. When tumor involvement of the nipple-areola complex (NAC), superficial margin, or posterior margin is confirmed by frozen section biopsy, additional resection including the skin and NAC, or postoperative radiotherapy, will be considered.
  • Procedure: Conventional nipple sparing mastectomy(CNSM) — Patients who undergo conventional nipple-sparing mastectomy (CNSM) with immediate breast reconstruction (IBR) will be enrolled in this group. CNSM is performed without the use of robotic or endoscopic surgical systems, and all types of skin incisions are permitted. During surgery, posterior areolar tissue sampling for frozen section biopsy is recommended. If suspicious lesions suggesting tumor involvement are identified at the superficial or posterior margins, frozen section biopsy should also be performed. When frozen section biopsy confirms tumor involvement of the nipple-areola complex (NAC), superficial margin, or posterior margin, additional excision including the skin and NAC, or postoperative radiotherapy, will be considered.

Primary Outcomes

  • 5-year disease-free survival rate(DFS) (The DFS period is calculated from the date of surgery to the time of the first event, or censored at the date of last follow-up if no event is reported.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-10-26
Completion: 2032-06
Eligibility
Age: 19 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 790 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yonsei University
Principal Investigators:
  • Hyung Seok Park, MD, PhD (PRINCIPAL_INVESTIGATOR) - Yonsei University
Contact Information
Study Contact:
Hyung Seok Park, MD, PhD
82-10-6760-2974
imgenius@yuhs.ac
Hee Jun Choi, M.D. PhD
82-10-9955-5801
heejun1.choi@samsung.com
Samsung Changwon Medical Center
Moo Hyun Lee, MD
82-10-2315-0197
mhlee197@gmail.com
Keimyung University Dongsan Hospital
Interventions
  • Procedure: Robot-assisted Nipple-Sparing Mastectomy (RNSM) — Patients undergoing robot-assisted nipple-sparing mastectomy (RNSM) with immediate breast reconstruction (IBR) will be enrolled in this group. RNSM will be performed using robotic surgical platforms, including the da Vinci S, Si, X, Xi, and SP systems. The procedure will be conducted through an axillary or lateral chest wall incision. During surgery, posterior areolar tissue sampling for frozen section biopsy will be recommended. If suspicious lesions are detected at the superficial or posterior margins, frozen section biopsy of those lesions will also be performed. When tumor involvement of the nipple-areola complex (NAC), superficial margin, or posterior margin is confirmed by frozen section biopsy, additional resection including the skin and NAC, or postoperative radiotherapy, will be considered.
  • Procedure: Conventional nipple sparing mastectomy(CNSM) — Patients who undergo conventional nipple-sparing mastectomy (CNSM) with immediate breast reconstruction (IBR) will be enrolled in this group. CNSM is performed without the use of robotic or endoscopic surgical systems, and all types of skin incisions are permitted. During surgery, posterior areolar tissue sampling for frozen section biopsy is recommended. If suspicious lesions suggesting tumor involvement are identified at the superficial or posterior margins, frozen section biopsy should also be performed. When frozen section biopsy confirms tumor involvement of the nipple-areola complex (NAC), superficial margin, or posterior margin, additional excision including the skin and NAC, or postoperative radiotherapy, will be considered.
Study Locations (17 sites)
Samsung Changwon Medical Center, Changwon, South Korea
Keimyung University Dongsan Hospital, Daegu, South Korea
Kyungpook National University Chilgok Hospital, Daegu, South Korea
Yeungnam University Medical Center, Daegu, South Korea
Myongji Hospital, Goyang-si, South Korea
The Catholic University of Korea, Incheon ST. Mary's Hospital, Incheon, South Korea
Kosin University Gospel Hospital, Pusan, South Korea
Chungnam National University Sejong Hospital, Sejong, South Korea
Asan Medical Center, Seoul, South Korea
Gangnam Severance Hospital, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria: * Adult women (≥19 years) scheduled to undergo therapeutic mastectomy for breast cancer who desire immediate breast reconstruction (IBR). * Breast cancer classified as clinical TNM stage 0 to IIIA, based on preoperative evaluation according to the 8th edition of the AJCC anatomic staging system. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion Criteria: * Patients scheduled for breast-conserving surgery or deemed ineligible for immediate breast reconstruction (IBR). * Clinical evidence of nipple or skin involvement on preoperative evaluation. * Pregnant or breastfeeding women. * Tumors consisting exclusively of lobular carcinoma in situ (LCIS). * Paget's disease of the breast. * Inflammatory breast cancer. * Male breast cancer. * Clinical stage IIIB-IV disease on preoperative evaluation. * breast size equal to or larger than cup E * History of breast cancer or bilateral breast cancer (including metachronous or synchronous disease). * History of non-breast malignancy, with the exception of non-melanoma skin cancer or papillary/follicular thyroid carcinoma. * Special histologic subtypes of breast tumors (e.g., phyllodes tumor, sarcoma, lymphoma). * Age \>70 years. * American Society of Anesthesiologists (ASA) physical status classification grade ≥4. * Inability to provide informed consent. * History of prior chest radiotherapy. * Patients who have not undergone preoperative testing for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV), which is required for liability insurance coverage.
Conditions Hypertension
Phase NA
Enrollment 200
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Two arm parallel randomized clinical trial

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: Digital Hypertension Management System — Mobile health technology using physician- directed, semi-automated management of hypertension
  • Other: Usual Care — The participants will receive usual care

Primary Outcomes

  • Defined Daily Dose (DDD) (Visit 1 (Baseline), Visit-3 (6 Month follow up))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-13
Completion: 2025-09-15
Eligibility
Age: 30 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Principal Investigators:
  • Paul J Wang, MD (PRINCIPAL_INVESTIGATOR) - Stanford University
Contact Information
Study Contact:
Paul J Wang, MD
(650) 723-9363
pjwang@stanford.edu
Meg Babakhanian, PhD
818-618-4764
mbabakha@stanford.edu
Paul Wang, MD
650-723-9363
pjwang@stanford.edu
Stanford Health Care
Interventions
  • Other: Digital Hypertension Management System — Mobile health technology using physician- directed, semi-automated management of hypertension
  • Other: Usual Care — The participants will receive usual care
Study Locations (3 sites)
Stanford Health Care, Palo Alto, California 94305 United States
Morehouse School of Medicine, Atlanta, Georgia 30310 United States
Lake Country Medical Group, Eatonton, Georgia 31024 United States
Eligibility Criteria
Inclusion Criteria: * Age 30-90 yrs. * Smartphone ownership * Office SBP: ≥ 140 mm Hg * ≤ 2 current anti-HTN meds * Able to add or dose-increase at least 2 of the following classes of medications: ACE-I/ARB, diuretic, calcium channel blocker, beta-blocker, mineralocorticoid receptor antagonists (i.e., at least 2 classes are available for addition or dose- increases after excluding intolerant medications and medications currently at maximum dose) * English or Spanish-speakers Exclusion Criteria: * Heart failure with reduced ejection fraction (EF \< 40%) * ESRD (GFR \<15) * Renal replacement therapy * Pregnant * Myocardial infarction or stroke within preceding 6 months * Hospitalization for hypertensive emergency or malignant hypertension within preceding 6 months * Prior solid organ transplantation * At the clinical discretion of the investigators * Enrolled in another clinical study
Conditions Diabetes Mellitus, Type 2, Nutrition Poo...
Phase NA
Enrollment 568
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a pragmatic randomized controlled trial (pRCT) that aims to test the effect of produce provision, diabetes education, and community referrals on hemoglobin A1c levels in individuals with type 2 diabetes experiencing food insecurity.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Mid-Ohio Food Farmacy — The Food Farmacy arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective.
  • Behavioral: Mid-Ohio Food Farmacy + Cooking for Diabetes — The Food Farmacy + Cooking for Diabetes Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention.
  • Behavioral: Mid-Ohio Food Farmacy + Health Impact Ohio Pathways Hub — The Food Farmacy + Health Impact Ohio Pathways Hub Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and has social needs address through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
  • Behavioral: Mid-Ohio Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub — The Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub Arm receives all 3 interventions. Participants receive weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective, Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention and has social needs addressed through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.

Primary Outcomes

  • Change in Hemoglobin A1c (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-02-06
Completion: 2026-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 568 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ohio State University
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Joshua Joseph, MD, MPH (PRINCIPAL_INVESTIGATOR) - Ohio State University
  • Daniel Walker, PhD (PRINCIPAL_INVESTIGATOR) - Ohio State University
Contact Information
Study Contact:
Luiza Reopell, BS
614-653-8213
luiza.reopell@osumc.edu
Daniel Walker, PhD
614-293-2428
Daniel.Walker@osumc.edu
Ashley Mintos, BS, CCRC
(614) 366-5504
Ashley.Mintos@osumc.edu
The Ohio State University Wexner Medical Center
Interventions
  • Behavioral: Mid-Ohio Food Farmacy — The Food Farmacy arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective.
  • Behavioral: Mid-Ohio Food Farmacy + Cooking for Diabetes — The Food Farmacy + Cooking for Diabetes Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention.
  • Behavioral: Mid-Ohio Food Farmacy + Health Impact Ohio Pathways Hub — The Food Farmacy + Health Impact Ohio Pathways Hub Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and has social needs address through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
  • Behavioral: Mid-Ohio Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub — The Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub Arm receives all 3 interventions. Participants receive weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective, Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention and has social needs addressed through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
Study Locations (1 sites)
The Ohio State University Wexner Medical Center, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: * Type 2 Diabetes based on American Diabetes Association Criteria * Hemoglobin A1c ≥ 7.5% * Screen Positive on 2-item Food Security Screener Exclusion Criteria: * Unwilling to Attest to Release of Information to Mid-Ohio Food Collective
Conditions Liver Diseases, Portal Hypertension
Phase PHASE3
Enrollment 660
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is an open-label, non-randomized trial that will be conducted at three clinical sites, Thomas Jefferson University (TJU), the Hospital of the University of Pennsylvania (HUP) and University of Bern (UB). Enrollment will be allocated into one of 4 different cohorts depending on the inclusion criteria for each cohort. Cohort 1: Patients scheduled for hepatic vein pressure gradient (HVPG) measurements will subsequently undergo two consecutive SHAPE (subharmonic aided pressure estimation) procedures using different ultrasound contrast agents (Definity \[Lantheus Medical Imaging, N Bilerica, MA, USA\] and Sonazoid \[GE Healthcare, Oslo, Norway\] in randomized order) to estimate portal pressures with a Logiq E10 scanner (GE Healthcare, Waukesha, WI, USA) and determine the reproducibility of the SHAPE algorithm. Cohort 2: Patients identified as having clinically significant portal hypertension (CSPH) will be monitored by SHAPE with Sonazoid for the duration of this project (18-24 months on average). These subjects will have follow-up ultrasound scans every 6 ± 2 months to check for hepatocellular carcinoma (HCC) (using the Barcelona-Liver Cancer staging system) as well as ascites and at those times a repeat SHAPE examination will be performed. Liver stiffness values will be measured with elastography as well. This cohort will examine if serial SHAPE can accurately predict development of ascites and other liver related events in patients with compensated cirrhosis undergoing routine HCC surveillance in a multi-center setting. Cohort 3: Subjects newly diagnosed with portal hypertension and starting treatment with non-selective β-blockers will be monitored with SHAPE and results compared to elastography measurements of liver stiffness with standard assessments (e.g., serum liver function tests and measurement of spleen size as well as platelet count). This cohort will establish if SHAPE can be used to monitor treatment response in patients identified with portal hypertension. Cohort 4: Patients with compensated advanced chronic liver disease scheduled for an endoscopy examination for screening of varices relative to the Baveno VI and the expanded-Baveno VI criteria as well as the AST to Platelet Ratio Index will undergo a SHAPE examination. This cohort will compare the predictive ability of SHAPE for allocating patients with compensated advanced chronic liver disease to screening of varices compared to the current standard of care.

Design

Study type: Interventional Phases: Phase3 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: SHAPE measurement (Sonazoid ultrasoud contrast agent) — Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
  • Drug: SHAPE measurement (Definity ultrasoud contrast agent) — Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min.

Primary Outcomes

  • Reproducibility of SHAPE liver pressure measurements (during procedure)
  • Number of subjects who develop ascites during follow-up (up to 18 months)
  • Number of subjects who experience clinical decompensation events (including the development of variceal bleeding) during follow-up (up to 18 months)
  • Number of subjects who present with esophageal or gastric varices on endoscopy (baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2022-11-28
Completion: 2026-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 660 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Thomas Jefferson University
Collaborators: University of Pennsylvania, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Bern
Principal Investigators:
  • Flemming Forsberg, PhD (PRINCIPAL_INVESTIGATOR) - Thomas Jefferson University
Contact Information
Study Contact:
Flemming Forsberg, PhD
215-955-4870
flemming.forsberg@jefferson.edu
Cynthia Miller, RN
215-955-8108
Cynthia.L.Miller.3@jefferson.edu
Michael Soulen, MD
215-615-3591
Michael.Soulen@pennmedicine.upenn.edu
University of Pennsylvania
Interventions
  • Drug: SHAPE measurement (Sonazoid ultrasoud contrast agent) — Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
  • Drug: SHAPE measurement (Definity ultrasoud contrast agent) — Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min.
Study Locations (3 sites)
University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States
Thomas Jefferson University, Dept of Radiology, Philadelphia, Pennsylvania 19107 United States
University of Bern, Bern, 3010 Switzerland
Eligibility Criteria
Inclusion Criteria: All subjects accepted for this trial must fulfill all the following criteria: * Be at least 18 years of age. * Be medically stable. * If a female of child-bearing potential, must have a negative pregnancy test. * Be conscious and able to comply with study procedures. * Have read and signed the IRB-approved Informed Consent form for participating in the study. Also there are specific inclusion criteria for each cohort: Cohort 1: • Be scheduled for transjugular liver biopsy where HVPG measurements will be obtained Cohort 2: • Have clinically significant portal hypertension undergoing routine HCC surveillance Cohort 3: • Have a diagnosis of portal hypertension and starting treatment with non-selective β-blockers Cohort 4: • Have clinically significant portal hypertension and be scheduled for endoscopy to screen for varices Exclusion Criteria: * Females who are pregnant or nursing. * Patients with pulmonary hypertension or unstable cardiopulmonary conditions * Patients currently on chemotherapy or with other primary cancers requiring systemic or hepatic loco-regional treatment. * Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example: * Patients on life support or in a critical care unit. * Patients with unstable occlusive disease (e.g., crescendo angina) * Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia. * Patients with uncontrolled congestive heart failure (NYHA Class IV) * Patients with recent cerebral hemorrhage. * Patients who have undergone surgery within 24 hours prior to the study sonographic examination. * Patients with a history of anaphylactic allergy to eggs or egg products, manifested by one or more of the following symptoms: generalized urticaria, difficulty in breathing, swelling of the mouth and throat, hypotension, or shock. (Subjects with nonanaphylactic allergies to eggs or egg products may be enrolled in the study, but must be watched carefully for 1 hour following the administration of Sonazoid). * Patients with congenital heart defects. * Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli. * Patients with respiratory distress syndrome * Patients with thrombosis within the hepatic, portal, or mesenteric veins. * Patients with grade 2 and above of hepatic encephalopathy within the last 3 months Also there is one additional exclusion criteria for cohort 1: • Patients with a history of anaphylactic allergy to perflutren (PEG) or any other components of Definity
Conditions Pulmonary Arterial Hypertension
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Patients with pulmonary arterial hypertension (PAH) have reduced health related quality of life (HRQOL) and impaired exercise capacity. Despite fourteen approved therapies, most patients die within ten years. Increasing physical activity is highly efficacious in PAH, resulting in six-minute walk distance (6MWD) and HRQOL improvement that often exceeds the effect of medications. Prior activity studies required inpatient rehabilitation, which is impractical, hard to sustain, and poorly scalable to a rare disease. The Investigators propose a randomized trial of smart texts versus usual care for 6 months. The Investigators will randomize 100 PAH patients to the mHealth intervention or usual care. The Investigators will test the effect of a text-based mHealth intervention on HRQOL in PAH using the PAH-specific emPHasis-10 questionnaire. The Investigators will also test the effect of an mHealth intervention on exercise capacity, measured by a supervised home-based 6MWD test. Finally, the Investigators will examine the effect of the intervention on time to clinical worsening (composite of PAH therapy escalation, PAH hospitalization, and death) one year after randomization.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: mHealth Intervention — The Health Insurance Portability and Accountability Act (HIPPA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network. Participants assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
  • Device: Usual Care — The HIPPA-compliant texting platform is linked to the Fitbit Application Program Interface. Real-time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network.

Primary Outcomes

  • Change in Quality of Life as measured by the Short Form Survey (SF-36) (Baseline to 24 weeks)
  • Change in Quality of Life as measured by the emPHasis-10 (Baseline to 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-01-01
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vanderbilt University Medical Center
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Evan Brittain, MD (PRINCIPAL_INVESTIGATOR) - Vanderbilt Medical Center
Contact Information
Study Contact:
Alisha Lindsey, RT
615-322-3412
alisha.lindsey@vumc.org
Evan Brittain, MD
615-322-2318
evan.brittain@vumc.org
Alisha Lindsey
alisha.lindsey@vumc.org
Vanderbilt University Medical Center
Interventions
  • Device: mHealth Intervention — The Health Insurance Portability and Accountability Act (HIPPA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network. Participants assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
  • Device: Usual Care — The HIPPA-compliant texting platform is linked to the Fitbit Application Program Interface. Real-time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network.
Study Locations (1 sites)
Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 or older. * Diagnosed with idiopathic, heritable, or associated (connective tissue disease, drugs, or toxins) pulmonary arterial hypertension (PAH), or PAH due to simple congenital heart disease (i.e. atrial septal defect). * WHO functional class I-III * Stable PAH-specific medication regimen for three months prior to enrollment. Subjects with only a single diuretic adjustment in the prior three months will be included. Adjustments in IV prostacyclin for side effect management are allowed. * Forced vital capacity \>65% predicted with no or minimal interstitial lung disease based on reviews of imaging studies by PI and medical monitor. Exclusion Criteria: * Prohibited from normal activity due to wheelchair bound status, bed bound status, reliance on a cane/walker, activity-limiting angina, activity-limiting osteoarthritis, or other condition that limits activity. * Pregnancy * Diagnosis of PAH etiology other than idiopathic, heritable, or associated. * Functional class IV heart failure * Requirement of \> 2 diuretic adjustment in the prior three months. * Preferred form of activity is not measured by an activity tracker (swimming, yoga, ice skating, stair master, or activities on wheels such as bicycling or rollerblading).
Conditions Breast Cancer, Screening
Phase Not Applicable
Enrollment 16164
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

An international multicenter study to prospectively validate the association between sonographic GTC and subsequent breast cancer risk in women with dense breasts.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Incident breast cancer within 3 months to 7 years after the assessment of sonographic GTC (from 3 months to 7 years after the GTC assessment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-11-01
Completion: 2031-12-30
Eligibility
Age: 40 Years and older
Sex: FEMALE
Volunteers: Not specified
Enrollment: 16164 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Seoul National University Hospital
Principal Investigators:
  • Woo Kyung Moon, MD, PhD (PRINCIPAL_INVESTIGATOR) - Seoul National University Hospital
Contact Information
Study Contact:
Woo Kyung Moon, MD, PhD
+82220722584
moonwk1963@gmail.com
Woo Kyung Moon
Seoul National University Hospital
Interventions
N/A
Study Locations (1 sites)
Seoul National University Hospital, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria 1. be ≥ 40 and \<70 years old at time of US 2. No history of previous breast cancer including DCIS 3. have dense breasts (BI-RADS category C and D on mammography performed within 12 months of breast US) and negative/benign BI-RADS assessment categories on mammography (BI-RADS 1, 2) 4. undergoing screening breast US using either automated or handheld device Exclusion Criteria 1. history of bilateral prophylactic mastectomy 2. history of bilateral foreign body injection 3. history of bilateral breast implants 4. history of bilateral breast reduction surgery or surgical excision 5. currently pregnant or breast feeding in the preceding 6 months 6. Known distant metastasis from other primary cancer
Conditions Breast Cancer
Phase Not Applicable
Enrollment 85
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to learn more about the challenges with breast cancer diagnosis in Tanzania and the support available to improve this process.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Behavioral: Focus group — A semi-structured focus group discussion guide will be developed with question probes that cover 1) contextual factors, 2) barriers to implementation, and 3) facilitators to implementation, with secondary probing questions.
  • Behavioral: Organizational Readiness for Implementing Change — measures the extent to which organizational members are prepared to implement organizational change. The ORIC tool asks participants to rate their level of agreement with 12 statements pertaining to organizational readiness for change (change commitment and change efficacy) on a 5-point Likert Scale.

Primary Outcomes

  • Identify barriers for breast cancer diagnosis in Tanzania. (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-04-13
Completion: 2027-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 85 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Diana Ng, MD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Diana Ng, MD
212-639-7209
NgD2@mskcc.org
T. Peter Kingham, MD
212-639-5260
kinghamP@mskcc.org
Diana Ng, MD
212-639-7209
NgD2@mskcc.org
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Interventions
  • Behavioral: Focus group — A semi-structured focus group discussion guide will be developed with question probes that cover 1) contextual factors, 2) barriers to implementation, and 3) facilitators to implementation, with secondary probing questions.
  • Behavioral: Organizational Readiness for Implementing Change — measures the extent to which organizational members are prepared to implement organizational change. The ORIC tool asks participants to rate their level of agreement with 12 statements pertaining to organizational readiness for change (change commitment and change efficacy) on a 5-point Likert Scale.
Study Locations (2 sites)
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York 10065 United States
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Eligibility Criteria
Participant Inclusion Criteria for interviews and focus group discussions (Aims 1 and 2): * Breast cancer survivor, patient advocate or key healthcare personnel * Key healthcare personnel are defined as hospital and laboratory leaders, pathologists, laboratory scientists and technicians, oncologists, nurses, and surgeons, with: * \>12 months of employment at the affiliated institution * Administrative or clinical involvement in the delivery of breast cancer care services. * Age 18 years and above * Permanent residents or citizens of Tanzania * Participant and/or LAR willing and able to consent * Fluent in Swahili and/or English by self-report Participant Exclusion Criteria: * Key stakeholder not residing at their particular institutions during data collection will be excluded. Eligibility criteria for Chart Reviews (Aim 1) Inclusion Criteria for chart review: * Age 18 years and above * Permanent residents or citizens of Tanzania * Received breast cancer diagnosis Exclusion Criteria for chart review: * Participants less than 18 years of age